The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.
Participant aged ≥ 18 years
ECOG Performance Status ≤ 3
Relapsed or refractory disease with at least 1 prior therapy OR
Ineligible for high-dose methotrexate-based therapy as determined by the treating physician, including previously untreated patients. Examples of medical conditions for which a patient could be considered ineligible for high-dose methotrexate include but not limited to renal impairment, liver disease, heart failure.
Concurrent use of other approved or investigational antineoplastic agents (with the exception of corticosteroids).
History of intracranial hemorrhage or clinically significant stroke within 6 months prior to enrollment
History of prior radiation to the CNS.
Significant medical diseases or conditions, as assessed by the investigator, that would substantially increase the risk-to-benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction in the past 6 months, unstable angina, uncontrolled diabetes mellitus, significant active infections, severely immunocompromised state, and congestive heart failure, New York Heart Association Class III-IV.
University of Utah
Lead sponsor
ADC Therapeutics S.A.
Collaborator